Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus MYCHEL.
MUPIROCIN vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category A/B
Category C
Antibiotic
Antibiotic